Literature DB >> 20465790

Bony metastases from breast cancer - a study of foetal antigen 2 as a blood tumour marker.

Kwok-Leung Cheung1, Ray K Iles, John F R Robertson.   

Abstract

BACKGROUND: Foetal antigen 2 (FA-2), first isolated in the amniotic fluid, was shown to be the circulating form of the aminopropeptide of the alpha 1 chain of procollagen type I. Serum concentrations of FA-2 appeared to be elevated in a number of disorders of bone metabolism. This paper is the first report of its role as a marker of bone metabolism in metastatic breast cancer.
METHODS: Serum FA-2 concentrations were measured by radioimmunoassay in 153 women with different stages of breast cancer and in 34 normal controls.
RESULTS: Serum FA-2 was significantly elevated in women with bony metastases (p < 0.015). Its levels were not significantly different among women with non-bony metastases, with non-metastatic disease, as well as among normal controls.
CONCLUSIONS: FA-2 is a promising blood marker of bone metabolism. Further studies to delineate its role in the diagnosis and management of bony metastases from breast cancer are required.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20465790      PMCID: PMC2879255          DOI: 10.1186/1477-7819-8-38

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


  12 in total

Review 1.  Tumour marker measurements in the diagnosis and monitoring of breast cancer.

Authors:  K L Cheung; C R Graves; J F Robertson
Journal:  Cancer Treat Rev       Date:  2000-04       Impact factor: 12.111

2.  New and traditional serum markers of bone metabolism in the detection of skeletal metastases.

Authors:  M Plebani; D Bernardi; M Zaninotto; M De Paoli; S Secchiero; L Sciacovelli
Journal:  Clin Biochem       Date:  1996-02       Impact factor: 3.281

3.  Development of a radioimmunoassay for fetal antigen 2.

Authors:  K M Price; R Silman; P Armstrong; J G Grudzinskas
Journal:  Clin Chim Acta       Date:  1994-01-14       Impact factor: 3.786

4.  Quantification of fetal antigen 2 (FA2) in supernatants of cultured osteoblasts, normal human serum, and serum from patients with chronic renal failure.

Authors:  H Boje Rasmussen; B Teisner; F Bangsgaard-Petersen; E Yde-Andersen; M Kassem
Journal:  Nephrol Dial Transplant       Date:  1992       Impact factor: 5.992

5.  Two fetal antigens (FA-1 and FA-2) and endometrial proteins (PP12 and PP14) isolated from amniotic fluid; preliminary observations in fetal and maternal tissues.

Authors:  T N Fay; I Jacobs; B Teisner; O Poulsen; M G Chapman; I Stabile; H Bohn; J G Westergaard; J G Grudzinskas
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1988-09       Impact factor: 2.435

6.  Fetal antigen 2: an amniotic protein identified as the aminopropeptide of the alpha 1 chain of human procollagen type I.

Authors:  B Teisner; H B Rasmussen; P Højrup; E Yde-Andersen; K Skjødt
Journal:  APMIS       Date:  1992-12       Impact factor: 3.205

7.  Serum levels of fetal antigen 2 in hyperthyroidism and primary hyperparathyroidism.

Authors:  H Boje Rasmussen; B Teisner; J Gram; K Brixen; E Yde-Andersen; J Bollerslev
Journal:  APMIS       Date:  1992-10       Impact factor: 3.205

8.  Serological monitoring of advanced breast cancer treated by systemic cytotoxic using a combination of ESR, CEA, and CA 15.3: fact or fiction?

Authors:  A R Dixon; I Jönrup; L Jackson; S Y Chan; R A Badley; R W Blamey
Journal:  Dis Markers       Date:  1991 May-Aug       Impact factor: 3.434

9.  Objective measurement of therapeutic response in breast cancer using tumour markers.

Authors:  J F Robertson; D Pearson; M R Price; C Selby; R W Blamey; A Howell
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

10.  Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers?

Authors:  A R Dixon; L Jackson; S Y Chan; R A Badley; R W Blamey
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.